

## Global Lucentis Ranibizumab Market Outlook 2025-2034: Growth Drivers, Share, And Trends

The Business Research Company's Lucentis Ranibizumab Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 18, 2025 /EINPresswire.com/ -- What Lies Ahead for the <u>Lucentis Ranibizumab Market</u>?



The Lucentis Ranibizumab market has experienced substantial growth in recent years and is expected to maintain this momentum in the coming years.

• The market size is projected to grow from \$3,538.57 million in 2024 to \$3,741.97 million in 2025, reflecting a compound annual growth rate (CAGR) of 5.7%.



Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!"

The Business Research
Company

- This expansion is driven by several factors, including:
- o Rising prevalence of age-related macular degeneration (AMD)
- o Regulatory approvals and reimbursement policies
- o Strong clinical efficacy and positive patient outcomes
- o Established brand recognition and physician adoption
- o Introduction of biosimilars and increasing cost competition
- By 2029, the market is anticipated to reach \$4,633.35 million, with a forecasted CAGR of 5.5%.
- Contributing factors to this growth include:
- o Increasing incidence of diabetic retinopathy (DR) and diabetic macular edema (DME)
- o Advancements in treatment protocols and combination therapies
- o An aging global population leading to a higher prevalence of retinal diseases
- o Expansion into emerging markets
- o Ongoing clinical research and potential new indications

Get Your Free Sample of The <u>Lucentis Ranibizumab Market Report</u>: <a href="https://www.thebusinessresearchcompany.com/sample.aspx?id=19907&type=smp">https://www.thebusinessresearchcompany.com/sample.aspx?id=19907&type=smp</a>

What Are the Key Growth Drivers and Trends in the Lucentis Ranibizumab Market?

A primary driver of market growth is the rising incidence of eye-related disorders. Factors contributing to the demand for Lucentis include the increasing prevalence of AMD and DME, influenced by aging, genetic predisposition, unhealthy lifestyle choices such as smoking and high-fat diets, and environmental factors like prolonged exposure to digital screens or sunlight. According to the National Eye Institute (USA), an estimated 2.2 million Americans will be blind by 2030, reinforcing the need for effective treatments like Lucentis Ranibizumab.

Another significant driver is the surge in healthcare spending. Increased investment in healthcare services and medical treatments, a rising aging population requiring specialized eye care, continuous advancements in medical technology, and a higher prevalence of chronic conditions contribute to the growing demand for Lucentis Ranibizumab.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/lucentis-ranibizumab-global-market-report

Which Companies Lead the Lucentis Ranibizumab Market? Major players dominating the market include F. Hoffmann-La Roche Ltd and Novartis AG.

What Are the Emerging Trends in the Lucentis Ranibizumab Market? The development of biosimilars is a key trend aimed at reducing treatment costs. Notable advancements include the launch of FYB201, a biosimilar of Lucentis Ranibizumab, developed by Formycon AG and Bioeq AG.

How is the Lucentis Ranibizumab Market Segmented?

- 1. By Type:
- o Single-use prefilled syringe
- o Single-use glass vial
- 2. By Application:
- o Age-related macular degeneration (AMD)
- o Diabetic retinopathy (DR)
- o Retinal vein occlusion (RVO)
- o Myopic choroidal neovascularization
- o Uveitis
- 3. By End-User:
- o Hospitals
- o Clinics
- o Ambulatory surgical centers
- o Other end-users

Which Regions Are Leading and Growing in the Lucentis Ranibizumab Market? North America held the dominant market share in 2024, while the Asia-Pacific region is projected to experience the fastest growth during the forecast period.

Browse more similar reports-

Retinal Vein Occlusion Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-global-market-report

Retinal Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report

Retinal Disorder Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report

## Learn More About The Business Research Company

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: <a href="https://in.linkedin.com/company/the-business-research-company">https://in.linkedin.com/company/the-business-research-company</a>

Twitter: https://twitter.com/tbrc\_info

YouTube: https://www.youtube.com/channel/UC24\_fl0rV8cR5DxlCpgmyFQ

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

Facebook

χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/794872360 EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.